Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.
Akira Onishi; Masao Tanaka; Takayuki Fujii; Koichi Murata; Kosaku Murakami; Motomu Hashimoto; Ryu Watanabe; Yuji Nozaki; Chisato Ashida; Wataru Yamamoto; Hirotaka Yamada; Sho Sendo; Kosuke Ebina; Hidehiko Makino; Yonsu Son; Yumiko Wada; Kenichiro Hata; Shuichi Matsuda; Akio Morinobu
Arthritis research & therapy, 2025年03月07日